Immuno Oncology Videos

Michael R. Grunwald, MD, director of the leukemia section in the department of hematologic oncology and blood disorders at the Levine Cancer Institute, Atrium Health, reviews an updated analysis of the phase 2 ELIANA trial, which confirmed the efficacy of a single infusion of the chimeric antigen receptor T-cell therapy tisagenlecleucel among children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia.